Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Synlogic closes $42mm Series C financing

Executive Summary

Synlogic Inc. raised $42mm through a Series C preferred stock financing to first-time backers Aju IB Investment, Ally Bridge Group, Arctic Aurora LifeScience, CLI Ventures, Perceptive Advisors, Rock Springs Capital, and other undisclosed new investors, which were joined by returning shareholders Atlas Venture, Deerfield, New Enterprise Associates, and OrbiMed. The financing was concurrent with the company announcing it is reverse merging with publicly traded Mirna Therapeutics Inc. The funds will enable Synlogic to move its lead metabolic programs through proof-of-concept and also develop early-stage candidates. Leerink Parnters was the placement agent.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies